Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29626829 | 0.86 | TSHR (0.54) | NCEH1TSHRCYP2A6CYP1A2ALDH1A1 | |
| SCHEMBL230034 | 0.86 | TSHR (0.54) | NCEH1TSHRCYP2A6CYP1A2ALDH1A1 | |
| SCHEMBL11575609 | 0.84 | TSHR (0.52) | NCEH1TSHRCYP2A6CYP1A2ALDH1A1 | |
| SCHEMBL224932 | 0.84 | HPGD (0.59) | TSHRCYP2A6CYP1A2ALDH1A1HPGD | |
| SCHEMBL6917579 | 0.82 | CYP1A2 (0.57) | TSHRCYP2A6CYP1A2ALDH1A1HPGD | |
| SCHEMBL6916502 | 0.82 | CYP1A2 (0.57) | TSHRCYP2A6CYP1A2ALDH1A1HPGD | |
| SCHEMBL6916761 | 0.82 | CYP1A2 (0.57) | TSHRCYP2A6CYP1A2ALDH1A1HPGD | |
| SCHEMBL6917031 | 0.82 | CYP1A2 (0.57) | TSHRCYP2A6CYP1A2ALDH1A1HPGD | |
| SCHEMBL6915993 | 0.82 | CYP1A2 (0.57) | TSHRCYP2A6CYP1A2ALDH1A1HPGD | |
| Ammonia Solution, Strong SCHEMBL7720483 | 0.82 | CYP1A2 (0.57) | TSHRCYP2A6CYP1A2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4364152-A | — | — | None | — | — | JP | disclosed |
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20160181543-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20100120700-A1 | METHODS AND COMPOSITIONS FOR TREATING CERVICAL CANCER | ARBOR VITA CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-0877012-A2 | Process for the production of high-purity dimethyl 2,6-naphthalenedicarboxylate and naphthalenedicarboxylic acid | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5792840-A | SUBSTITUTED GLUCOPYRANOSYL PHOSPHATES | SANKYO COMPANY, LIMITED (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0437016-B1 | Lipid A analogues having immunoactivating and anti-tumour activity | SANKYO CO (JP) | 1996-05-01 | — | — | EP | disclosed |
| JP-H04364152-A | METHOD FOR RECOVERING CATALYST | TEIJIN LTD | 1992-12-16 | — | — | JP | disclosed |
| EP-0291172-B1 | KETONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
| US-5084474-A | Antagonist of 5-hydroxytryptamine receptors on nerves and useful for treatment of psychotic disorders, anxiety, and nausea and vomiting, compounds of imidazole | GLAXO GROUP LIMITED (GB) | 1992-01-28 | — | — | US | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-5019586-A | 5-Hydroxytryptamine Receptor Antagonists | GLAXO GROUP LIMITED | 1991-05-28 | — | — | US | disclosed |
| US-4918080-A | ANXIOLYTIC AGENTS, ANTIEMETICS | GLAXO GROUP LIMITED (GB) | 1990-04-17 | — | — | US | disclosed |
| EP-0291172-A1 | Ketone derivatives | GLAXO GROUP LIMITED (GB) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | PTGER2, PTGER1, PTGDR2 | NCEH1 1668/4885TSHR 207/4885CYP2A6 434/4885 |
| US-20100120700-A1 | METHODS AND COMPOSITIONS FOR TREATING CERVICAL CANCER | MAGI3, PDLIM5, PYM1 | NCEH1 2175/4885TSHR 4574/4885CYP2A6 4866/4885 |
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | XIAP, BIRC3, BIRC2 | NCEH1 3430/4885TSHR 4244/4885CYP2A6 3819/4885 |
| US-20160181543-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE | RER1, LEF1, RPL18 | NCEH1 544/4885TSHR 383/4885CYP2A6 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.